MX2009007911A - Inhibidores de proteina tirosina fosfatasa 1b aromaticos fusionados. - Google Patents

Inhibidores de proteina tirosina fosfatasa 1b aromaticos fusionados.

Info

Publication number
MX2009007911A
MX2009007911A MX2009007911A MX2009007911A MX2009007911A MX 2009007911 A MX2009007911 A MX 2009007911A MX 2009007911 A MX2009007911 A MX 2009007911A MX 2009007911 A MX2009007911 A MX 2009007911A MX 2009007911 A MX2009007911 A MX 2009007911A
Authority
MX
Mexico
Prior art keywords
ptp
inhibitors
fused aromatic
formula
encompasses
Prior art date
Application number
MX2009007911A
Other languages
English (en)
Inventor
Claude Dufresne
John Colucci
Yongxin Han
Marie-Claire Wilson
Michel Belley
Cheuk K Lau
Christopher Bayly
Original Assignee
Merck Frosst Canada Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada Ltd filed Critical Merck Frosst Canada Ltd
Publication of MX2009007911A publication Critical patent/MX2009007911A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/60—Quinoline or hydrogenated quinoline ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3834—Aromatic acids (P-C aromatic linkage)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención abarca la clase novedosa de compuestos representados por la fórmula siguiente: (ver fórmula I) los cuales son inhibidores de la enzima PTP-1 B; la invención abarca también composiciones farmacéuticas que incluyen los compuestos mostrados (de fórmula 1) anteriores, y métodos para tratar o prevenir enfermedades mediadas por PTP-1 B, incluyendo diabetes.
MX2009007911A 2007-01-26 2008-01-24 Inhibidores de proteina tirosina fosfatasa 1b aromaticos fusionados. MX2009007911A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89770007P 2007-01-26 2007-01-26
PCT/CA2008/000172 WO2008089581A1 (en) 2007-01-26 2008-01-24 Fused aromatic ptp-1b inhibitors

Publications (1)

Publication Number Publication Date
MX2009007911A true MX2009007911A (es) 2009-07-31

Family

ID=39644072

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009007911A MX2009007911A (es) 2007-01-26 2008-01-24 Inhibidores de proteina tirosina fosfatasa 1b aromaticos fusionados.

Country Status (17)

Country Link
US (4) US8168815B2 (es)
EP (1) EP2114971B1 (es)
JP (1) JP5570223B2 (es)
KR (1) KR101568799B1 (es)
CN (1) CN102317296B (es)
AU (1) AU2008209296B2 (es)
BR (1) BRPI0806789B8 (es)
CA (1) CA2675142C (es)
DK (1) DK2114971T3 (es)
ES (1) ES2547386T3 (es)
HK (1) HK1165806A1 (es)
IL (1) IL199742A (es)
MX (1) MX2009007911A (es)
NZ (2) NZ600947A (es)
RU (1) RU2462469C2 (es)
WO (1) WO2008089581A1 (es)
ZA (1) ZA200904679B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2462469C2 (ru) * 2007-01-26 2012-09-27 Канек Фарма Инк. Конденсированные ароматические дифторметанфосфонаты в качестве ингибиторов протеинтирозинфосфатазы ib (ptp-1b)
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
AU2013248880A1 (en) 2012-04-16 2014-11-06 Kaneq Pharma Inc. Fused aromatic phosphonate derivatives as precursors to PTP-1B inhibitors
WO2014141110A2 (en) * 2013-03-14 2014-09-18 Curadev Pharma Pvt. Ltd. Aminonitriles as kynurenine pathway inhibitors
JP2017513812A (ja) 2014-02-28 2017-06-01 ザ ロイヤル インスティチューション フォー ジ アドヴァンスメント オブ ラーニング／マギル ユニヴァーシティ 免疫療法用のａｐｃ活性剤としてのｔｃ−ｐｔｐ阻害剤
CN108159069A (zh) * 2018-01-26 2018-06-15 广东省微生物研究所（广东省微生物分析检测中心） 灰树花多糖f2在制备治疗高脂血症药物、预防或延缓动脉粥样硬化药物中的应用
WO2023220833A1 (en) * 2022-05-19 2023-11-23 Kanyr Pharma Inc. Combined inhibition of tyrosine phosphatases tcptp and ptp1b and pd-1 blockage immunotherapy in the treatment of cancer
WO2024123585A1 (en) * 2022-12-05 2024-06-13 Merck Sharp & Dohme Llc Substituted quinazoline derivatives and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI83421C (fi) * 1989-06-21 1991-07-10 Huhtamaeki Oy Foerfarande foer framstaellning av farmakologiskt anvaendbara metylenbisfosfonsyraderivat.
AU1856997A (en) 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
US6174874B1 (en) * 1998-09-21 2001-01-16 Merck Frosst Canada & Co. Phosphonic acids derivatives as inhibitors of protein tyrosine phosphate 1B (PTP-1B)
WO2001046206A1 (en) * 1999-12-22 2001-06-28 Merck Frosst Canada & Co. Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1b (ptp-1b)
EP1268495A1 (en) * 2000-03-22 2003-01-02 Merck Frosst Canada Inc. Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors
CA2415742A1 (en) 2000-07-25 2002-01-31 Merck & Co., Inc. N-substituted indoles useful in the treatment of diabetes
ES2342596T3 (es) 2002-08-29 2010-07-09 MERCK SHARP & DOHME CORP. Indoles con actividad anti-diabetica.
US7608590B2 (en) * 2004-01-30 2009-10-27 Medivir Ab HCV NS-3 serine protease inhibitors
JP4922924B2 (ja) 2004-04-13 2012-04-25 メルク・シャープ・エンド・ドーム・コーポレイション Ｃｅｔｐ阻害薬
DOP2005000123A (es) 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
NZ554783A (en) * 2004-11-15 2010-12-24 Ceptyr Inc Protein tyrosine phosphatase inhibitors and methods of use thereof
RU2462469C2 (ru) * 2007-01-26 2012-09-27 Канек Фарма Инк. Конденсированные ароматические дифторметанфосфонаты в качестве ингибиторов протеинтирозинфосфатазы ib (ptp-1b)

Also Published As

Publication number Publication date
US20120178679A1 (en) 2012-07-12
AU2008209296A1 (en) 2008-07-31
EP2114971A1 (en) 2009-11-11
CA2675142C (en) 2014-08-19
RU2462469C2 (ru) 2012-09-27
US20100022477A1 (en) 2010-01-28
JP5570223B2 (ja) 2014-08-13
IL199742A (en) 2014-03-31
JP2010516715A (ja) 2010-05-20
IL199742A0 (en) 2010-04-15
BRPI0806789B1 (pt) 2020-01-28
KR20090108102A (ko) 2009-10-14
HK1165806A1 (en) 2012-10-12
US9334295B2 (en) 2016-05-10
DK2114971T3 (en) 2015-08-31
US8927526B2 (en) 2015-01-06
AU2008209296B2 (en) 2012-12-20
US20130281365A1 (en) 2013-10-24
CN102317296A (zh) 2012-01-11
ZA200904679B (en) 2010-04-28
EP2114971A4 (en) 2011-07-06
CN102317296B (zh) 2015-05-27
NZ578296A (en) 2012-07-27
ES2547386T3 (es) 2015-10-05
KR101568799B1 (ko) 2015-11-12
NZ600947A (en) 2012-12-21
US8481742B2 (en) 2013-07-09
CA2675142A1 (en) 2008-07-31
RU2009132092A (ru) 2011-03-10
US8168815B2 (en) 2012-05-01
EP2114971B1 (en) 2015-06-17
US20150045325A1 (en) 2015-02-12
BRPI0806789A2 (pt) 2011-09-13
BRPI0806789B8 (pt) 2021-05-25
WO2008089581A1 (en) 2008-07-31

Similar Documents

Publication Publication Date Title
MX2009007911A (es) Inhibidores de proteina tirosina fosfatasa 1b aromaticos fusionados.
ATE449097T1 (de) Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer
EA201100311A1 (ru) Амидные производные гетероарилов и их применение в качестве активаторов глюкокиназы
MX2010009752A (es) Compuestos de oxadiazoantraceno para el tratamiento de diabetes.
GEP20135964B (en) Inhibitors of beta-secretase
WO2009152356A3 (en) Compounds and compositions useful for the treatment of malaria
TW200732296A (en) Novel compounds
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
MX2009007944A (es) Compuestos y composiciones de purina como inhibidores de quinasa para el tratamiento de enfermedades relacionadas con plasmodium.
NO20093009L (no) Kondensert ring heterocykel kinase modulatorer
WO2008131000A3 (en) 7-substituted indole mcl-1 inhibitors
UA103930C2 (ru) Соединения и композиция для лечения паразитарных болезней
WO2010151799A3 (en) Compounds for modulating rna binding proteins and uses therefor
PH12014501199A1 (en) Substituted 4-phenyl - pyridines for the treatment of nk-1 receptor related diseases
GEP20135724B (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for treatment or prevention of diabetes
MX2010003685A (es) Analogos de quinolona y metodos relacionados con los mismos.
EA201100749A1 (ru) Производные пиридина и пиримидина в качестве ингибиторов фосфодиэстеразы 10
MX2010003117A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
MX2012002542A (es) Compuestos y composiciones como inhibidores de cinasa de proteina.
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
WO2010151797A3 (en) Compounds for modulating rna binding proteins and uses therefor
MX2012002366A (es) Agonistas novedosos de receptores beta 3 andrenergicos derivados de pirrolidina.
WO2007053765A3 (en) Substituted cycloalkylpyrrolones as allosteric modulators of glucokinase
WO2010079431A3 (en) Compounds for the prevention and treatment of cardiovascular disease
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof

Legal Events

Date Code Title Description
GB Transfer or rights
FG Grant or registration